Please login to the form below

Not currently logged in

Allergan resists Valeant's advances

Valeant Pharma logo

Threatens to derail proposed $45bn merger

NICE rejects Roche's Kadcyla as "unaffordable"

Roche Kadcyla trastuzumab emtansine cancerCancer drug unable to justify £90,000 price tag

FDA approves Janssen drug for rare Castleman’s disease

FDA headquarters White OakSylvant approved to treat lymphoma-like condition

Publicis recruits Kylie Minogue for French cancer campaign

Kylie Minogue cancer campaignAustralian singer is taking centre stage in a new Alliance for Research in Cancer initiative

NICE backs two cancer drugs

National Institute for Health and Care Excellence NICE logoBoehringer’s Giotrif and Janssen’s Velcade given final go-ahead for NHS use

Pfizer set to file Xeljanz for psoriasis

Pfizer headquartersSet to add another indication after positive study results

Valeant offers $45.7bn for Botox firm Allergan

Valeant Pharma logoTrend for major pharma deals continues

Pfizer rumoured to be after AstraZeneca

Pfizer AstraZenecaIs this the return of the pharma mega-merger?

Novartis pays $16bn for GSK's oncology portfolio

Novartis buildingSwiss company strikes series of deals, including one to step away from vaccines

Sex is a good trick

But pharma companies - and payers - should stop incestuous ‘best practice’ behaviours and look for new ways of comparing options

Latest appointments

Featured jobs

Subscribe to our email news alerts


Add my company
grey healthcare group - London

Contagious Thinking™ is how ghg gets human and animal health brands deeply engaged in critical conversations with KOLs, healthcare professionals,...

Latest intelligence

Designing Human Experiences
Applying science to the creative process to improve lives...
Assured Global Delivery at The Right Temperature®
CSafe Global partners with DHL Global Forwarding to assure pharmaceutical manufacturer successful temperature sensitive delivery to South America....
The changing regulatory environment
Code of practice changes are encouraging transparency in pharma/HCP relationships...